Dupixent Lawsuit Guide 2025: Eligibility, Side Effects & Compensation
If you or a loved one developed cancer after using Dupixent for eczema, asthma, or other inflammatory conditions, you may be entitled to significant compensation. This comprehensive guide explains everything you need to know about Dupixent lawsuits in 2025, including eligibility requirements, potential settlements, and how to file a claim.
The first Dupixent wrongful death lawsuit was filed in October 2025. Litigation is actively developing, and filing deadlines may apply.
What is Dupixent and what is it prescribed for?
Dupixent (dupilumab) is a prescription biologic medication approved by the U.S. Food and Drug Administration for treating several inflammatory conditions.
Manufactured by Sanofi and Regeneron Pharmaceuticals, Dupixent has become one of the world's best-selling drugs, generating over $11 billion in annual sales.
FDA-approved uses for Dupixent include atopic dermatitis (eczema) in moderate-to-severe cases for patients 6 months and older, moderate-to-severe eosinophilic or oral corticosteroid-dependent asthma in patients 6 years and older, chronic rhinosinusitis with nasal polyps in adults with inadequate response to nasal corticosteroids, eosinophilic esophagitis in patients 12 years and older weighing at least 40 kg, and prurigo nodularis in adults with inadequately controlled disease.
Dupixent works by blocking interleukin-4 (IL-4) and interleukin-13 (IL-13), signaling proteins that play a central role in type 2 inflammation. By inhibiting these pathways, Dupixent reduces inflammation and related symptoms.
The medication is administered as a subcutaneous injection, typically given every two weeks after an initial loading dose. Most patients use Dupixent for extended periods—often months or years—to manage chronic inflammatory conditions.
What side effects have led to Dupixent lawsuits?
The primary serious side effect driving Dupixent litigation is an increased risk of cutaneous T-cell lymphoma (CTCL), a rare form of non-Hodgkin lymphoma that affects the skin.
A 2023 study published in JAMA Dermatology analyzed data from over 20,000 patients and found that Dupixent users faced a 4.5 times higher risk of developing CTCL compared to patients not using the drug (Ständer et al., JAMA Dermatology, 2023). The increased risk appeared dose-dependent, with longer duration of use correlating to higher cancer rates.
Types of cutaneous T-cell lymphoma associated with Dupixent include mycosis fungoides, the most common form characterized by patches, plaques, and tumors on the skin, Sézary syndrome, an aggressive form involving widespread red, itchy skin and cancer cells in the blood, primary cutaneous CD30+ lymphoproliferative disorders, and subcutaneous panniculitis-like T-cell lymphoma.
Symptoms of CTCL that Dupixent users should watch for include persistent skin rashes that don't respond to treatment, scaly or discolored patches or plaques, thickened or hardened skin lesions, tumors or nodules on the skin, intense itching (pruritus), swollen lymph nodes, hair loss in affected areas, and nail changes or abnormalities.
Beyond cancer risks, Dupixent has been associated with other serious adverse events. Eye and vision problems, including conjunctivitis, keratitis, dry eye, blurred vision, and eye pain affect approximately 10% of users. Other reported issues include increased susceptibility to parasitic helminth (worm) infections, severe allergic reactions such as anaphylaxis, serum sickness, and angioedema, elevated eosinophil counts sometimes with systemic symptoms, and significant joint pain and arthralgia in some patients.
The manufacturers added warnings about conjunctivitis and keratitis to Dupixent's labeling, but critics argue the cancer risks were not adequately disclosed to patients and healthcare providers.
Learn more about Dupixent side effects
Am I eligible for a Dupixent lawsuit?
To qualify for a Dupixent lawsuit in 2025, you must meet specific criteria related to your medication use and subsequent diagnosis.
Dupixent usage duration: You must have used Dupixent for 3 months or longer. Longer usage periods (6+ months, 1+ years) typically strengthen claims. Prescription records and pharmacy documentation establish usage.
Cancer diagnosis: You must be diagnosed with cutaneous T-cell lymphoma (CTCL), specifically mycosis fungoides or Sézary syndrome. Diagnosis must be confirmed through skin biopsy and pathology report. Symptoms must have appeared 30+ days after starting Dupixent.
Timeline requirements: Cancer diagnosis must have occurred while using Dupixent or within reasonable time after discontinuing (typically within 2 years). You must be able to provide medical records documenting both medication use and diagnosis.
Legal standing: You must have no active or recent bankruptcy filings. Certain felony convictions may disqualify plaintiffs. The statute of limitations must not have expired in your state (varies by jurisdiction).
Additional factors that may strengthen your case include severity of diagnosis, with advanced-stage CTCL or aggressive disease progression carrying more weight, age at diagnosis, with younger patients having longer life expectancy, treatment burden, measured by the extent of chemotherapy, radiation, or other intensive treatments required, impact on quality of life including disfigurement, disability, or loss of normal activities, and economic damages such as significant medical expenses, lost income, or reduced earning capacity.
Patients who used Dupixent for less than 3 months, those diagnosed with cancers other than CTCL (though this may change as litigation develops), individuals with pre-existing lymphoma before starting Dupixent, and cases where the statute of limitations has expired may not qualify.
If a loved one died from CTCL after using Dupixent, surviving family members may be eligible to file a wrongful death claim. Eligible family members typically include spouses, children, parents, and in some states, siblings or other dependents.
Check if you qualify for a Dupixent lawsuit
What compensation can Dupixent victims receive?
While Dupixent litigation is in early stages and no settlements have been publicly disclosed as of early 2025, we can estimate potential compensation based on similar pharmaceutical mass tort cases.
Economic damages cover actual financial losses. Medical expenses include cancer diagnosis costs (biopsies, imaging, lab work), chemotherapy and radiation treatments, medications and supportive care, hospitalizations and surgeries, ongoing monitoring and follow-up care, and future medical costs for chronic CTCL management. Lost income and wages encompass time off work for treatments and recovery, reduced earning capacity due to disability, lost career advancement opportunities, and inability to return to previous employment. Out-of-pocket expenses include travel to medical appointments, home healthcare and assistance, medical equipment and supplies, and modifications to home or vehicle.
Non-economic damages address intangible losses. Pain and suffering covers physical discomfort from cancer and treatments. Emotional distress includes anxiety, depression, and PTSD related to diagnosis. Loss of enjoyment of life reflects inability to participate in previously enjoyed activities. Disfigurement and scarring result from visible skin lesions and treatment effects. Loss of consortium captures impact on relationships with spouse and family.
Wrongful death damages, when applicable, include funeral and burial expenses, loss of financial support the deceased would have provided, loss of companionship and guidance, and estate claims for the decedent's pain and suffering before death.
While each case is unique, similar pharmaceutical injury cases provide benchmarks. Minor to moderate CTCL cases may result in $250,000 to $750,000 for early-stage diagnosis with successful treatment, limited ongoing medical needs, and minimal long-term impact on daily life. Serious CTCL cases typically range from $750,000 to $2,000,000 for advanced disease requiring aggressive treatment, permanent disfigurement or disability, ongoing medical monitoring requirements, and significant impact on quality of life and employment. Severe or fatal cases may reach $2,000,000 to $5,000,000+ for life-threatening complications, need for stem cell transplant or intensive treatments, permanent disability, and wrongful death claims.
Factors affecting individual settlement amounts include strength of causation evidence, with medical records clearly linking Dupixent to CTCL, severity and stage of cancer, since advanced disease typically results in higher compensation, age and life expectancy, as younger plaintiffs may receive more for lost future earnings, treatment intensity, where extensive chemotherapy, radiation, or transplant increases damages, quality of life impact measured by degree of disfigurement, disability, or lifestyle limitations, pre-existing conditions, which may reduce damages, and state of residence, as jury awards and damage caps vary significantly by jurisdiction.
Based on other mass tort litigation patterns, bellwether trials (test cases) will likely occur in 2026-2027, establishing baseline settlement values. These initial verdicts create negotiating frameworks for remaining cases. A tier system typically organizes cases by severity, with Tier 1 representing most severe injuries and highest compensation, Tier 2 covering moderate injuries and impacts, and Tier 3 addressing minor injuries or minimal damages. Global settlement funds may be established if enough cases consolidate, allowing faster resolution than individual trials. Attorney fees and costs are typically handled on contingency (no upfront cost), with lawyers receiving 33-40% of any settlement or verdict, plus reimbursement for case expenses.
View detailed Dupixent settlement information
How long do Dupixent lawsuits take?
The timeline for Dupixent litigation depends on several factors, including when you file, case complexity, and whether cases settle or go to trial.
As of 2025, the first Dupixent wrongful death lawsuit was filed in October 2025. Additional individual cases are expected to be filed in late 2025 and early 2026. Potential formation of Multi-District Litigation (MDL) may occur in 2026 if enough federal cases are filed. The discovery phase, including document production and depositions, will span 2026-2027. Anticipated bellwether trial selections and first trial dates are expected in 2027.
During months 1-6 (case filing and intake), initial consultations with attorneys occur, medical records are collected, cases are investigated and researched, and formal complaints are filed in court. Months 6-18 (consolidation and organization) see cases consolidated into MDL, lead counsel and steering committees appointed, and master complaints and common discovery plans developed. Months 18-36 (discovery phase) involve document requests to Sanofi and Regeneron, expert witness retention and reports, depositions of company officials, scientists, and plaintiffs, and analysis of internal company documents and studies. Months 36-48 (bellwether trials) include selection of representative test cases, first trials to verdict, and results that inform settlement negotiations. Months 48+ (settlement or individual trials) bring global settlement negotiations based on bellwether outcomes and individual case settlements or trials for non-settling plaintiffs.
Given the litigation's early stage in 2025, if you file in 2025-2026, potential resolution may occur in 2027-2029 (2-4 years). If cases consolidate quickly, settlements could begin after first bellwether trials (3-4 years). If litigation is protracted, some cases may extend 5-7 years, particularly if multiple trial phases occur.
Strong scientific evidence with clear causation links accelerates settlements. Adverse publicity in the form of negative media coverage incentivizes manufacturers to settle. Unfavorable bellwether verdicts, particularly large plaintiff verdicts, encourage global settlements. FDA actions such as warning label changes or market restrictions increase settlement pressure.
Manufacturer defenses through aggressive litigation strategies by Sanofi and Regeneron can delay resolution. Scientific disputes involving debates over causation and alternative explanations extend timelines. Individual case complexity, particularly plaintiffs with pre-existing conditions or multiple exposures, slows progress. Appeals by defendants of adverse verdicts add significant time.
During litigation, plaintiffs should expect ongoing medical documentation requirements by continuing treatment and keeping detailed records. Periodic updates from attorneys provide regular communication about case status. Possible depositions may require you to provide sworn testimony. Medical examinations may be requested by the defense through independent medical exams. Settlement offers may arrive before trial. Decision points will require choosing whether to accept settlements or proceed to trial.
In certain situations, cases may be expedited for terminal illness or advanced age, with preference given to plaintiffs with limited life expectancy. Extreme financial hardship in some jurisdictions allows expedited trials for economic necessity. Bellwether selection, being chosen as a test case, accelerates your individual timeline. However, these are exceptions rather than the rule. Most plaintiffs should anticipate multi-year timelines.
While Dupixent litigation will take years to resolve, filing early in the process can provide advantages. Early filers may be selected for bellwether trials, which can lead to earlier settlements. Additionally, statutes of limitations may bar claims if you wait too long.
Understand the Dupixent filing process
What evidence do I need for a Dupixent claim?
Building a strong Dupixent lawsuit requires comprehensive documentation linking your medication use to your cancer diagnosis. The more complete your evidence, the stronger your claim.
Dupixent prescription and usage records should include prescription history showing dates when Dupixent was prescribed, dosage, and frequency, pharmacy records providing proof of prescription fills, dates, and quantities dispensed, medical notes from your doctor's records indicating why Dupixent was prescribed and the condition being treated, duration documentation showing a clear timeline of 3+ months of continuous or intermittent use, lot numbers identifying specific product batches if available, and insurance claims in the form of Explanation of Benefits (EOBs) showing Dupixent costs covered.
Cancer diagnosis documentation encompasses pathology reports with skin biopsy results confirming CTCL diagnosis, diagnostic imaging such as CT scans, PET scans, or MRI showing disease extent, laboratory results including blood work showing lymphoma markers and eosinophil counts, staging information documenting cancer stage (IA through IVB for CTCL), specialist consultations from oncology and dermatology records, and flow cytometry results analyzing cancerous cells.
Treatment records consist of chemotherapy protocols listing specific drugs, dosages, and cycles administered, radiation therapy documentation including treatment plans, doses, and affected areas, surgical procedures covering skin lesion removals and lymph node biopsies, supportive care records for medications addressing side effects and pain management, hospital admissions documenting inpatient stays for treatment complications, and clinical trial participation if enrolled in experimental treatments.
Timeline and causation evidence includes medical history showing you did not have CTCL before starting Dupixent, symptom onset documentation of when skin changes first appeared, temporal relationship establishing clear connection between Dupixent use and cancer development, other exposure history proving you weren't exposed to other known CTCL causes, and alternative causes ruled out through testing that excluded other lymphoma triggers.
Economic damage documentation requires medical bills for all invoices related to diagnosis, treatment, and follow-up care, insurance statements showing EOBs with amounts paid and patient responsibility, out-of-pocket expenses with receipts for medications, supplies, and travel, employment records including pay stubs, W-2s, and tax returns showing income, lost wage verification through employer letters documenting missed work, and future cost estimates from medical opinions on ongoing treatment needs.
Quality of life impact evidence comprises photographs showing before and after images of visible skin changes and disfigurement, daily journals with personal records of pain levels, limitations, and emotional state, testimony from family members with statements from loved ones about impact on daily activities, mental health records documenting treatment for depression, anxiety, and PTSD related to diagnosis, and life care plans providing expert assessments of future needs and accommodations.
Attorneys use this evidence to establish the four elements of product liability. They must prove defective product through evidence that Dupixent caused CTCL risk not adequately warned about, causation via medical proof linking your specific cancer to Dupixent use, injury through documentation of CTCL diagnosis and resulting harm, and damages via records quantifying financial losses and suffering.
Your attorney will likely retain medical experts who will review your evidence and provide opinions on whether Dupixent caused your CTCL, whether the standard of care was met and warnings were adequate, what future medical needs and costs you face, and the extent of permanent impairment or disability.
If you're missing some evidence, attorneys can request records from providers by subpoenaing medical records you can't obtain directly, reconstruct timelines using partial records and witness statements to fill gaps, work with experts to have specialists review available evidence and provide opinions, and obtain testimony by deposing your treating physicians to establish facts.
To organize your evidence, create a timeline with a chronological list of Dupixent use, symptoms, diagnosis, and treatments. Separate by category including medical, financial, employment, and personal impact. Make copies and never provide original documents without keeping duplicates. Highlight key dates marking when Dupixent started, symptoms began, and cancer was diagnosed. Prepare a summary with a written overview of your experience in your own words.
To protect your evidence, continue medical treatment as ongoing documentation strengthens claims. Follow doctor's orders since gaps in treatment can be used against you. Avoid social media as defense attorneys review posts for inconsistent statements. Keep records secure by storing documents safely and making backups. Don't destroy anything since even seemingly unimportant records may have value.
Consulting with an experienced mass tort attorney early allows them to advise what additional evidence to gather and helps you avoid common mistakes that could weaken your claim.
Take action: Free Dupixent lawsuit evaluation
If you or a loved one developed cutaneous T-cell lymphoma (CTCL), mycosis fungoides, or Sézary syndrome after using Dupixent, you may be entitled to significant compensation for medical expenses, lost wages, pain and suffering, and other damages.
Mass tort attorneys work on contingency, meaning no upfront costs. Filing deadlines exist due to statutes of limitations that may bar claims if you wait too long. Early filers may benefit from potential bellwether selection and earlier settlements. Free consultations allow you to find out if you qualify with no obligation. Even if you're still being treated, you can preserve your claim.
The next steps involve completing a free case evaluation to see if you qualify, gathering your medical records showing Dupixent use and CTCL diagnosis, speaking with an attorney who specializes in pharmaceutical injury cases, and filing your claim before deadlines expire.
The manufacturers of Dupixent generated billions in sales from this medication. If they failed to adequately warn patients about serious cancer risks, they should be held accountable.
Find out if you qualify for compensation
Disclaimer: This article is for informational purposes only and does not constitute medical or legal advice. The information presented is based on publicly available research and legal filings as of 2025. Dupixent lawsuit outcomes cannot be guaranteed, and settlement amounts will vary based on individual circumstances. If you have health concerns about Dupixent, consult your physician. For legal advice about a potential claim, speak with a qualified mass tort attorney.
References
This information is based on peer-reviewed medical research and court filings:
-
Hasan, I., Parsons, L., Duran, S., & Zinn, Z. (2024). Dupilumab therapy for atopic dermatitis is associated with increased risk of cutaneous T cell lymphoma: A retrospective cohort study. Journal of the American Academy of Dermatology, 91(2), 255-258. View study
-
Mandel, J., Mehta, J., Hafer, R., Ayub, M., Nusrat, F., Yang, H., Porcu, P., & Nikbakht, N. (2024). Increased Risk of Cutaneous T-Cell Lymphoma Development after Dupilumab Use for Atopic Dermatitis. Dermatologic Therapy, 2024, 9924306. View study
Information last updated: November 2025